You are here

Control of Scar Contracture After Burn Injury Topical Formulation

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W81XWH-13-C-0051
Agency Tracking Number: H122-016-0058
Amount: $149,920.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: DHP12-016
Solicitation Number: 2012.2
Solicitation Year: 2012
Award Year: 2013
Award Start Date (Proposal Award Date): 2013-04-24
Award End Date (Contract End Date): 2013-11-28
Small Business Information
Photonic Systems Division 1845 W. 205th Street
Torrance, CA -
United States
DUNS: 153865951
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 Anya Asanbaeva
 (310) 320-3088
Business Contact
 Gordon Drew
Title: Chief Financial Officer
Phone: (310) 320-3088
Research Institution

The overall incidence of burns in current military operations has nearly doubled during the past few years and this type of injury remains a common component of armed conflicts. To address the need for prevention of scar contracture following burns, Physical Optics Corporation (POC) proposes to develop a new Control of Scar Contracture After Burn injury (SCAB) topical formulation. The SCAB is designed for application to burn-injured tissue after debridement during the critical initial stages of wound healing. Inhibition of contracture by SCAB is done by (1) stimulating the cells, thereby enhancing healing, and (2) controlling the stability of the collagen network. This dual action of the SCAB formulation on the cellular component and on the extracellular matrix constitutes the main innovation of the proposed solution. As a result, the SCAB formulation offers a safe and efficacious biomodulator of scar contracture supplied in a pharmaceutical delivery medium. In Phase I, POC will develop the SCAB formulation and demonstrate its efficacy in vitro and in a pilot animal study, validating the therapeutic effect of and setting the foundation for the formulation of the final product. In Phase II, further therapeutic efficacy characterization of SCAB will be performed with detailed animal studies.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government